Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.

Recruiting Observational Study
Pulmonary Hypertension Due to Left Heart Disease Pulmonary Hypertension (PH) Heart Failure
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
150 (estimated)
Sponsor
Hospital General Universitario Gregorio Marañon · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin. Focusing on dysregulation of the BMPR2-activin pathway, a key regulator of vascular homeostasis, this project uses a multimodal approach combining molecular biology, advanced cardiac imaging, and histology. Its aim is to determine the role of the B…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Older that 18 years * Heart failled patients with clinical indication for invasive hemodynamic assessment * Written consent Exclusion Criteria: * Refulsl to sign the infomred consent * Presence of iodinated contrast allergy * Ineligibility for HT (for BREATHE-CT substudy)
Contacts

Ana I Fernandez-Avila, PhD

+34650413943

afernandeza.externo@salud.madrid.org

CONTACT

Jorge Martinez-Solano, MD, PhD

jmsolano@salud.madrid.org

CONTACT